Sirnaomics (2257) H2 2025 earnings summary

Executive summary

• Achieved significant clinical milestones in RNAi therapeutics, advancing late-stage programs for oncology, aesthetics, and cardiometabolic diseases.

• Completed Phase I trials for STP705 (focal fat reduction) and STP707 (solid tumors), with robust safety and efficacy data.

• Advanced GalAhead™ platform, with STP122G in final Phase I cohort and IND-enabling work for STP125G completed.

• Implemented comprehensive restructuring, reducing costs and focusing resources on high-potential assets.

• Expanded intellectual property portfolio, now holding over 110 patents and applications globally.

Financial highlights

• No revenue generated in 2025; 2024 revenue was $1.8 million from licensing.

• Loss for 2025 narrowed to $14.6 million from $50.2 million in 2024, driven by lower R&D and administrative expenses.

• Administrative expenses fell 71% to $5.0 million; R&D expenses dropped 50% to $10.3 million.

• Cash and cash equivalents increased to $13.5 million as of December 31, 2025.

• Net cash used in operating activities reduced by 53% to $9.2 million.

Outlook and guidance

• Targeting NDA filing for STP705 by 2027, pending regulatory approval and funding.

• Preparing IND submissions for GalAhead™ candidates STP125G and STP144G in 2026.

• Focused on commercializing STP705 and expanding into new therapeutic areas.